BIONANO GENOMICS INC (BNGO) Stock Price & Overview

NASDAQ:BNGO • US09075F4046

Current stock price

1.155 USD
+0.03 (+3.13%)
Last:

The current stock price of BNGO is 1.155 USD. Today BNGO is up by 3.12%. In the past month the price decreased by -3.45%. In the past year, price decreased by -65.54%.

BNGO Key Statistics

52-Week Range1.06 - 5.5
Current BNGO stock price positioned within its 52-week range.
1-Month Range1.08 - 1.181
Current BNGO stock price positioned within its 1-month range.
Market Cap
11.758M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-20.56
Dividend Yield
N/A

BNGO Stock Performance

Today
+3.12%
1 Week
N/A
1 Month
-3.45%
3 Months
-30.00%
Longer-term
6 Months -37.43%
1 Year -65.54%
2 Years -98.32%
3 Years -99.83%
5 Years -99.98%
10 Years N/A

BNGO Stock Chart

BIONANO GENOMICS INC / BNGO Daily stock chart

BNGO Technical Analysis

ChartMill assigns a technical rating of 0 / 10 to BNGO. When comparing the yearly performance of all stocks, BNGO is a bad performer in the overall market: 94.17% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

BNGO Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to BNGO. While BNGO seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

BNGO Earnings

On November 13, 2025 BNGO reported an EPS of -1.59 and a revenue of 7.37M. The company beat EPS expectations (18.39% surprise) and beat revenue expectations (5.12% surprise).

Next Earnings DateMar 30, 2026
Last Earnings DateNov 13, 2025
PeriodQ3 / 2025
EPS Reported-$1.59
Revenue Reported7.367M
EPS Surprise 18.39%
Revenue Surprise 5.12%

BNGO Forecast & Estimates

9 analysts have analysed BNGO and the average price target is 7.65 USD. This implies a price increase of 562.34% is expected in the next year compared to the current price of 1.155.

For the next year, analysts expect an EPS growth of 92.31% and a revenue growth -2.01% for BNGO


Analysts
Analysts80
Price Target7.65 (562.34%)
EPS Next Y92.31%
Revenue Next Year-2.01%

BNGO Groups

Sector & Classification

Index Membership

BNGO Financial Highlights

Over the last trailing twelve months BNGO reported a non-GAAP Earnings per Share(EPS) of -20.56. The EPS increased by 77.75% compared to the year before.


Income Statements
Revenue(TTM)28.72M
Net Income(TTM)-38.59M
Industry RankSector Rank
PM (TTM) N/A
ROA -48.81%
ROE -77.49%
Debt/Equity 0.07
Chartmill High Growth Momentum
EPS Q2Q%93.38%
Sales Q2Q%-9.75%
EPS 1Y (TTM)77.75%
Revenue 1Y (TTM)-13.84%

BNGO Ownership

Ownership
Inst Owners10.61%
Shares10.18M
Float9.33M
Ins Owners3.19%
Short Float %12.5%
Short Ratio5.9

About BNGO

Company Profile

BNGO logo image Bionano Genomics, Inc. is a life sciences instrumentation company, which focuses on the genome analysis space. The company is headquartered in San Diego, California and currently employs 98 full-time employees. The company went IPO on 2018-08-01. The firm offers optical genome mapping (OGM) solutions for applications across basic, translational and clinical research. The company also offers a platform-agnostic software solution, which integrates sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants, and absence of heterozygosity across the genome in one consolidated view. The firm additionally offers nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. The firm markets and sells OGM systems, including the Saphyr system, which delivers OGM data to enable ultra-sensitive and ultra-specific detection of all classes of structural variation (SV).

Company Info

IPO: 2018-08-01

BIONANO GENOMICS INC

9540 Towne Centre Drive, Suite 100

San Diego CALIFORNIA 92121 US

CEO: R. Erik Holmlin

Employees: 99

BNGO Company Website

BNGO Investor Relations

Phone: 18588887600

BIONANO GENOMICS INC / BNGO FAQ

Can you describe the business of BIONANO GENOMICS INC?

Bionano Genomics, Inc. is a life sciences instrumentation company, which focuses on the genome analysis space. The company is headquartered in San Diego, California and currently employs 98 full-time employees. The company went IPO on 2018-08-01. The firm offers optical genome mapping (OGM) solutions for applications across basic, translational and clinical research. The company also offers a platform-agnostic software solution, which integrates sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants, and absence of heterozygosity across the genome in one consolidated view. The firm additionally offers nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. The firm markets and sells OGM systems, including the Saphyr system, which delivers OGM data to enable ultra-sensitive and ultra-specific detection of all classes of structural variation (SV).


Can you provide the latest stock price for BIONANO GENOMICS INC?

The current stock price of BNGO is 1.155 USD. The price increased by 3.12% in the last trading session.


What is the dividend status of BIONANO GENOMICS INC?

BNGO does not pay a dividend.


What is the ChartMill technical and fundamental rating of BNGO stock?

BNGO has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.


What is the analyst forecast for BNGO stock?

9 analysts have analysed BNGO and the average price target is 7.65 USD. This implies a price increase of 562.34% is expected in the next year compared to the current price of 1.155.


Can you provide the sector and industry classification for BIONANO GENOMICS INC?

BIONANO GENOMICS INC (BNGO) operates in the Health Care sector and the Life Sciences Tools & Services industry.


Is BIONANO GENOMICS INC (BNGO) expected to grow?

The Revenue of BIONANO GENOMICS INC (BNGO) is expected to decline by -2.01% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.